Lotus Eye Hospital and Institute Limited

Lotus Eye Hospital and Institute Limited (LOTUSEYE) is a micro-cap Healthcare company valued at ₹237 crore operating in Hospital on the NSE and BSE.

Recent price move

Lotus Eye Hospital and Institute Limited last traded at ₹112.51, up 2.84% on the day.

Recent developments

On 2026-06-30, the company reported its latest quarter results, showing a net profit of ₹1 crore, matching the same quarter a year earlier. Promoter shares pledged reached 87.15% of promoter holding as of 2026-06-30, indicating significant leverage.

Financial performance

The company's annual revenue rose 8.4% to ₹54 crore, but net profit fell to ₹0 crore, a decline of 89.2% from ₹1 crore. In the latest quarter, revenue increased 26.2% to ₹17 crore, while net profit remained flat at ₹1 crore compared to the same quarter a year earlier.

Valuation multiples

The stock trades at 2812.8 times earnings, a premium to the Healthcare median of 32.0, 3.84 times book value. It yields 0.5%.

Things to watch

The company reported an annual net profit of ₹0 crore, down 89.2% from ₹1 crore. The net profit margin fell to 0.1%, a decline of 1.3 percentage points from 1.5% the prior year. Promoter shares pledged account for 87.15% of promoter holding, raising concerns about liquidity.

Where it stands

The company ended the latest quarter with a net profit of ₹1 crore, matching the same quarter a year earlier, but reported an annual net profit of ₹0 crore. The net profit margin has dropped significantly, and promoter shares pledged now account for 87.15% of promoter holding.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.